PuSH - Publikationsserver des Helmholtz Zentrums München: Screening for type 1 diabetes in the general population: A status report and perspective.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Sims, E.K.* ; Besser, R.E.J.* ; Dayan, C.* ; Geno Rasmussen, C.* ; Greenbaum, C.J.* ; Griffin, K.J.* ; Hagopian, W.* ; Knip, M.* ; Long, A.E.* ; Martin, F.* ; Mathieu, C.* ; Rewers, M.* ; Steck, A.K.* ; Wentworth, J.M.* ; Rich, S.S.* ; Kordonouri, O.* ; Ziegler, A.-G. ; Herold, K.C.*

Screening for type 1 diabetes in the general population: A status report and perspective.

Diabetes 71, 610-623 (2022)

Postprint

DOI

PMC

	Open Access Green

Abstract
Metriken
Zusatzinfos

Most screening programs to identify individuals at risk for type 1 diabetes have targeted relatives of people living with the disease to improve yield and feasibility. However, ∼90% of those who develop type 1 diabetes do not have a family history. Recent successes in disease-modifying therapies to impact the course of early-stage disease have ignited the consideration of the need for and feasibility of population screening to identify those at increased risk. Existing population screening programs rely on genetic or autoantibody screening, and these have yielded significant information about disease progression and approaches for timing for screening in clinical practice. At the March 2021 Type 1 Diabetes TrialNet Steering Committee meeting, a session was held in which ongoing efforts for screening in the general population were discussed. This report reviews the background of these efforts and the details of those programs. Additionally, we present hurdles that need to be addressed for successful implementation of population screening and provide initial recommendations for individuals with positive screens so that standardized guidelines for monitoring and follow-up can be established.

Impact Factor

Scopus SNIP

Altmetric

9.337

0.000